688105 Stock Overview
Offers technology solutions for life science, biomedicine, and in vitro diagnostics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nanjing Vazyme Biotech Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥24.36 |
| 52 Week High | CN¥38.72 |
| 52 Week Low | CN¥16.85 |
| Beta | 1.01 |
| 11 Month Change | -2.36% |
| 3 Month Change | 26.74% |
| 1 Year Change | -33.46% |
| 33 Year Change | -78.80% |
| 5 Year Change | n/a |
| Change since IPO | -71.46% |
Recent News & Updates
Nanjing Vazyme Biotech's (SHSE:688105) Shareholders May Want To Dig Deeper Than Statutory Profit
Nov 07
Nanjing Vazyme Biotech Co., Ltd's (SHSE:688105) 45% Price Boost Is Out Of Tune With Revenues
Oct 08Recent updates
Nanjing Vazyme Biotech's (SHSE:688105) Shareholders May Want To Dig Deeper Than Statutory Profit
Nov 07Nanjing Vazyme Biotech Co., Ltd's (SHSE:688105) 45% Price Boost Is Out Of Tune With Revenues
Oct 08Is Nanjing Vazyme BiotechLtd (SHSE:688105) Using Debt In A Risky Way?
Jun 26Nanjing Vazyme Biotech Co.,Ltd's (SHSE:688105) Shares Climb 31% But Its Business Is Yet to Catch Up
Mar 06Shareholder Returns
| 688105 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -0.6% | -2.6% | -2.1% |
| 1Y | -33.5% | -20.9% | 2.8% |
Return vs Industry: 688105 underperformed the CN Biotechs industry which returned -20.9% over the past year.
Return vs Market: 688105 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 688105 volatility | |
|---|---|
| 688105 Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688105's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688105's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2,637 | Lin Cao | www.vazyme.com |
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers reagents for molecular biology research, such as nucleic acid extraction, PCR, cloning/mutagenesis, nucleic acid electrophoresis, reverse transcription, real-time PCR (qPCR), genome editing, and cell biology/protein research; reagents for NGS library preparation, including automated liquid handling workstation, DNA sequencing, RNA sequencing, single cell-seq series, epigenetics series, beads series, quantification series, and capture series; reagents for molecular diagnosis comprising isothermal amplification reagents, PCR, reverse transcription, real-time PCR, one-step series, and animal detection; and reagents for bio-medicine, such as vaccine effectiveness evaluations and vaccine manufacture. Nanjing Vazyme Biotech Co., Ltd was founded in 2012 and is based in Nanjing, China.
Nanjing Vazyme Biotech Co., Ltd Fundamentals Summary
| 688105 fundamental statistics | |
|---|---|
| Market cap | CN¥9.63b |
| Earnings (TTM) | CN¥23.59m |
| Revenue (TTM) | CN¥1.40b |
408.2x
P/E Ratio6.9x
P/S RatioIs 688105 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688105 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.40b |
| Cost of Revenue | CN¥553.22m |
| Gross Profit | CN¥849.39m |
| Other Expenses | CN¥825.80m |
| Earnings | CN¥23.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 29, 2024
| Earnings per share (EPS) | 0.06 |
| Gross Margin | 60.56% |
| Net Profit Margin | 1.68% |
| Debt/Equity Ratio | 11.6% |
How did 688105 perform over the long term?
See historical performance and comparison